Please ensure Javascript is enabled for purposes of website accessibility
Micro-Cap Insider
Micro stocks. Maximum profits

July 6, 2022

Not surprisingly with the holiday weekend, last week was a quiet week. And I bet this week will be quiet too.
But we did get some good news!

Hope you had a wonderful 4th of July.

We didn’t travel far – just to Wenham, MA to visit our in-laws. The trip was great. We ate a lot of good BBQ, spent time with family, and got two beach days in at Singing Beach in Manchester-by-the-Sea.

This year was the first year that we brought my kids (4 and 6) to the fireworks. Although they loved the fireworks, I think they were most excited to be able to stay up until 9:30pm (well past bedtime).

Not surprisingly with the holiday weekend, last week was a quiet week. And I bet this week will be quiet too.

But we did get some good news!

NexPoint’s (NXDT) long-awaited transition to REIT is complete!

NexPoint issued a press release stating that the transition is complete and that the company will move forward to create shareholder value. The company highlighted several properties that are ripe for value creation:

  • Cityplace Tower which is in Uptown, Dallas. NexPoint is redeveloping the property and has been negotiating lease terms with several high-profile tenants. The project includes plans to develop a five-star InterContinental® Hotel within the building.
  • VineBrook Homes Trust, Inc., a single-family rental company that owns over 21,000 homes in 23 markets.
  • Two private self-storage companies, including NexPoint Storage Partners, the product of NexPoint’s take-private acquisition of former publicly traded self-storage REIT Jernigan Capital, Inc. in November 2020.

The press release also notes that two other REIT’s – NexPoint Residential Trust, Inc. (NXRT) and NexPoint Real Estate Finance, Inc. (NREF) – were incubated within NexPoint Diversified REIT before being spun out. Those REIT’s have performed well with total returns of 460% and 35%, respectively.

I expect the company to start scheduling quarterly earnings and conference calls regularly to update investors on its strategy.

The thesis remains on track, and I see ~50% upside in the next 12 months. As such, I’m increasing my buy limit to “Buy under 17.00.”

Original Write-Up. Buy under 17.00

The next issue of Cabot Micro-Cap Insider will be published on Wednesday, July 13. As always, if you have any questions, please email me at

Changes This Week
Increase limit on NXDT to Buy under 17.00

Aptevo (APVO) announced positive data during the week of June 9th from its phase 1b trial in MDS patients treated with APVO436. 36% of patients achieved a remission. As of March 31, 2022, Aptevo has $30MM of net cash and expects to receive an additional $22.5MM over the next few years. Aptevo’s cash burn over the past year was $22MM. As such, it can probably make it another two years without raising cash. However, the company probably does want to raise capital at some point. From a fundamental perspective, Aptevo continues to report good data for its lead compound APVO436 in patients with acute myeloid leukemia (AML). This biotech bear market is no fun, but Aptevo continues to be an asymmetric bet. Original Write-up. Buy under 7.50

Atento S.A. (ATTO) had no news this week. The company reached a settlement with an activist investor, Kyma Capital, in early June. Kyma owns 8.5% of the company. Under the terms of the agreement, Kyma will get a board seat and will work with the Board of Directors to evaluate all options to increase shareholder value. Kyma also has permission to increase its position to 19.9%. While the most recent quarter was weak, the stock looks very cheap. And the agreement is a positive. Atento is trading at just 3x EBITDA while peers trade at closer to 12x EBITDA. Original Write-up. Buy under 20.00

Cipher Pharma (CPHRF) had no news this week. The company reported earnings in May. They were great. Revenue was flat year over year, but EPS increased from $0.05 last year to $0.08 this year. The EPS increase was driven by cost cutting (operating expenses decreased 25%). Meanwhile, ~2% of shares were repurchased during the quarter. Currently has $22MM of net cash on its balance sheet, representing 48% of the company’s market cap. Cash flow should be stable for at least the next 4-5 years which will provide time for the pipeline to emerge. The company continues to move its pipeline forward and evaluate accretive acquisition opportunities. Original Write-up. Buy under 2.00

Cogstate Ltd (COGZF) has had no recent news, but we will get a financial update in July. Cogstate is a profitable, rapidly growing Australian company that is the market leader in computerized cognition testing. The biggest use case is Alzheimer’s Disease, which is a massive and growing market. Cogstate is benefiting from a boom in Alzheimer’s R&D spending which is driving 20%+ revenue growth. Longer term, Cogstate’s direct-to-consumer Alzheimer’s test could accelerate growth even further. Despite a terrific outlook, Cogstate trades at just 24x current earnings. Looking out a few years, this stock could easily double or more. Original Write-up. Buy under 1.80

Crossroads Systems (CRSS) reported earnings on June 14th. The company doesn’t share too much information when it reports earnings, but the key takeaways for me were the following: 1) impact loan generated $1.5MM of net income in the quarter or $6MM on an annualized basis 2) the impact loan portfolio continues to grow the company’s recently announced partnership with Enhanced Capital. The stock is trading at ~12x annualized net income (from impact loans) which seems far too cheap given 1) strong growth potential in the impact loan market and 2) the management team and board of directors have a track record of creating shareholder value (the company paid a special dividend of $40/per share in 2021 due to windfalls from the PPP program). Original Write-up. Buy under 15.00

Currency Exchange International (CURN) reported earnings on June 14th. Results were strong, but not strong enough as the stock has sold off. Revenue increased 109% y/y to $13.3MM. Net operating income increased to $2.9MM up from a loss of $0.6MM last year. Both Banknotes (+103%) and Payments (+127%) grew very strongly. Importantly, management noted that it expects a strong summer travel season which should drive (my opinion) record results. The stock continues to look very cheap. Original Write-up. Buy under 16.00

Dorchester Minerals LP (DMLP) has pulled back a bit with oil prices, but I think it continues to look compelling. Dorchester’s latest distribution was $0.75, which annualizes to an 11.3% yield. The company is benefiting from high commodity prices. While commodity prices will continue to be volatile, I expect them to remain elevated for the foreseeable future. Dorchester will pay out all windfall profits to shareholders. Original Write-up. Buy under 25.00

Epsilon Energy (EPSN) announced that its CEO and CFO are both retiring and will be replaced effective July 1, 2022. I’ve gotten more color on this announcement and understand that it was part of a planned transition and that the CEO and CFO will both stay on as consultants for some time. While natural gas prices have pulled back, they remain quite elevated. Last year, the company produced tremendous free cash flow and will likely do so again this year. The company currently has $30MM of cash (20% of its market cap) and no debt. Epsilon recently committed to paying a quarterly dividend of $0.0625 per share starting on March 31. This works out to a 5.0% dividend yield. In addition, the company is actively buying back shares (1.1MM share repurchase authorization). Original Write-up. Buy under 8.00

Esquire Financial Holdings (ESQ) had no news this week. It initiated a nine-cent quarterly dividend in April. This works out to a 1% yield. The company reported earnings in late March. Results were excellent, and the investment case remains on track. The company reported Q2 EPS of $0.66, a penny ahead of consensus. Return on equity increased y/y from 13.3% to 15.0%. Esquire remains well capitalized with excellent credit metrics. The company has a long runway for growth, as articulated by CEO Andrew Sagliocca: “There is tremendous potential in both the litigation and payment markets primarily due to the limited number of players and fragmented and inefficient approach to coupling financing, payment processing, and technology. We believe Esquire will be a leader in all three categories in both industries.” Despite its strong outlook, the stock trades at just 12x earnings. Original Write-up. Buy under 35.00

IDT Corporation (IDT) announced quarterly results in early June, and the stock sold off. At a high level, the quarter didn’t look great. Revenue decreased 12% y/y which was driven by a 17% decline in traditional communications revenue. This segment benefitted from the boom in paid calling during the pandemic, but that surge is normalizing. Most importantly, IDT’s high-growth segments continue to grow well. National Retail Solutions (NRS), IDT’s payment terminal business, grew 102% y/y. Net2phone, IDT’s other highly valuable subsidiary, grew recurring revenue by 42%. Further, IDT expects subsidiary growth to contribute to consolidated profitability in the second half of this year. While the spin-off of net2phone has been temporarily delayed, we know that it and NRS will ultimately be monetized. The investment case remains on track and my price target is 55 based on an updated sum-of-the-parts analysis. Original Write-up. Buy under 45.00

Liberated Syndication (LSYN) has had no news recently. However, I had a chance to speak to the CEO on June 20th. He said the team is working through re-filing its financials, and he expects to “go public” again by the end of September. Instead of just “turning on” trading, he would like to raise a little capital and also pick up some coverage from some sell-side analysts. He noted the advertising business is growing very well and that the podcast hosting business is growing again. It had experienced limited growth last year given free hosting competition, but business has picked back up. While Libsyn has been a frustrating stock, I think (and hope!) our patience will be rewarded by the end of September. Original Write-up. Buy under 5.00

Medexus Pharma (MEDXF) reported a strong quarter on June 22. Revenue increased 15% y/y to $20.4MM and EBITDA in the quarter was $1.1MM, up from -$1.6MM last year. IXINITY has returned to normal sales patterns which closely align with underlying patient demand. The company also benefited from its launch of Gleolan in the United States. If/when treosulfan is approved, Medexus will have to pay Medac milestone payments of $15MM to $45MM depending on the label. Medexus is evaluating financing options to pay the milestone payments with a number of interested parties. Medexus continues to be optimistic that Medac will provide the FDA with all the data that it needs by July 2022 and that treosulfan will ultimately be approved. Liquidity remains strong as the company has $10MM of cash on hand and the business is growing again. I continue to think the risk/reward profile of Medexus is asymmetric to the upside. Original Write-up. Buy under 3.50

NexPoint Diversified REIT (NXDT) was covered above.

P10 Holdings (PX) reported another great quarter in May. Revenue increased 32% to $43.3MM while adjusted EBITDA increased 31% to $22.5MM. Assets under management increased 34% to $17.6BN. Higher assets under management will drive continued revenue and earnings growth. The company also announced a $20MM share repurchase. P10 is currently trading at 15x 2022 adjusted EBITDA which is a very reasonable valuation for such a stable business with strong organic growth potential. Original Write-up. Buy under 15.00

RediShred (RDCPF) had no news this week. It is my latest recommendation. It’s a Canada-based, leading document destruction services company. Insiders own more than 30% of the company. It has grown revenue at a 31% CAGR and EBITDA at an 80% CAGR over the past 10 years through organic and inorganic growth. Future growth is poised to continue, yet the stock trades at just 5x forward EBITDA. I see 100% upside over the next 12 months and significantly more upside looking out a few years. Original Write-up. Buy under 0.70

Truxton (TRUX) reported another great quarter in April, with the company reporting its best quarterly earnings ever. The private banking team continues to grow assets in the Nashville area and rising rates are benefiting the portfolio’s net interest margin. Asset quality remains sound with $0 in non-performing loans and $0 in net charge-offs (that’s pretty good!). The Truxton investment case remains on track. The bank will continue to grow loans and earnings prudently while returning excess cash to shareholders through dividends and share buybacks. The stock is trading at just 12.3x annualized earnings. This isn’t the most exciting stock, but it’s a slow and steady winner. Original Write-up. Buy under 75.00

Zedge Inc (ZDGE) reported earnings on June 13. The stock fell as revenue grew by 18% but declined sequentially. Monthly active users (MAUs) in both developing and developed countries fell sequentially. However, management noted that MAUs are growing again and that they are cautiously optimistic that these trends will continue. Further, the recent quarter included no contribution from the recent acquisition of GuruShots. Given strong recent insider buying, I’m expecting positive news when we hear more details about the integration of GuruShots. The stock remains very cheap trading at 3.4x EBITDA. Original Write-up. Buy under 6.00

Price on
Aptevo Therapeutics (APVO)32.013/10/213.77-88%Buy under 7.50
Atento SA (ATTO)21.578/24/219.31-57%Buy under 20.00
Cipher Pharma (CPHRF)1.8010/11/211.78-1%Buy under 2.00
Cogstate Ltd (COGZF)1.704/13/221.05-38%Buy under 1.80
Crossroad Systems (CRSS)14.102/9/2212.50-11%Buy under 15.00
Currency Exchange (CURN)14.1005/11/2212.12-14%Buy under 16.00
Dorchester Minerals LP (DMLP)*10.4510/14/2024.32133%Buy under 25.00
Epsilon Energy (EPSN)5.008/11/215.6012%Buy under 8.00
Esquire Financial Holdings (ESQ)34.1110/10/2134.361%Buy under 35.00
IDT Corporation (IDT)19.372/10/2125.0229%Buy under 45.00
Liberated Syndication (LSYN)3.066/10/203.7523%Buy under 5.00
Medexus Pharma (MEDXF)1.785/13/201.50-16%Buy under 3.50
NexPoint Diversified Real Estate
Trust (NXDT)
14.151/12/2216.2515%Buy under 17.00
P10 Holdings (PX)**2.984/28/2011.86298%Buy under 15.00
Truxton Corp (TRUX)*72.2512/8/2165.00-9%Buy under 75.00
Zedge (ZDGE)5.733/9/222.72-53%Buy under 6.00

Disclosure: Rich Howe owns shares in LSYN, MEDXF, PIOE, IDT, APVO, DMLP, and NXDT. Rich will only buy shares after he has shared his recommendation with Cabot Micro-Cap Insider members.

Buy means accumulate shares at or around the current price.*Includes dividends received
Hold means just that; hold what you have. Don’t buy, or sell, shares.
Sell means the original reasons for buying the stock no longer apply, and I recommend exiting the position.
Sell a Half means it’s time to take partial profits. Sell half (or whatever portion feels right to you) to lock in a gain and hold on to the rest until another ratings change is issued.